Factors modifying drug and placebo responses in randomized trials for bipolar mania


YILDIZ A., Vieta E., Tohen M., Baldessarini R. J.

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, vol.14, no.7, pp.863-875, 2011 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 14 Issue: 7
  • Publication Date: 2011
  • Doi Number: 10.1017/s1461145710001641
  • Journal Name: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.863-875
  • Keywords: Bipolar I disorder, mania, meta-analysis, placebo response, randomized controlled trials, RELEASE CARBAMAZEPINE CAPSULES, SODIUM EXTENDED-RELEASE, DOUBLE-BLIND, CLINICAL-TRIALS, MIXED EPISODES, ARIPIPRAZOLE MONOTHERAPY, RISPERIDONE MONOTHERAPY, MOOD DISORDERS, I DISORDER, MULTICENTER
  • Dokuz Eylül University Affiliated: No

Abstract

Randomized placebo-controlled trials (RCTs) are standard for assessing efficacy and safety of treatments. We pursued preliminary indications that some factors are associated differentially with responses to placebo or drugs in RCTs for bipolar mania. We meta-analysed data from RCTs to assess influences of study-site count, subjects' age, sex distribution, diagnostic subgroups, clinical features, trial-completion rates, and publication year on mean difference (MD) in mania ratings between intake and final assessments. In 38 RCTs involving 3812 placebo-treated and 6988 drug-treated patients, symptomatic improvement was similar in placebo arms of trials of effective (6.77, 95% CI 5.77-7.76) and ineffective (7.61, 95% CI 5.47-8.75) drugs. Lesser placebo responses (MD) and greater drug-placebo differences (Hedges' g) were associated with fewer study sites, younger patients' age, and male sex. More patients with initial psychotic features and more trial completion in drug arms were associated with greater drug-associated improvement (MD) and drug-placebo contrast (Hedges' g), whereas more mixed-state diagnoses decreased both measures. Identifying modifying factors can support more efficient and cost-effective designs of therapeutic trials. In trials for mania, fewer sites may limit placebo response and enhance drug-placebo contrasts.